Literature DB >> 1533758

Left ventricular mass in diabetes-hypertension.

E Grossman1, J Shemesh, A Shamiss, M Thaler, J Carroll, T Rosenthal.   

Abstract

BACKGROUND: This study was undertaken to identify whether diabetes mellitus (DM) accelerates the development of left ventricular hypertrophy (LVH) in hypertensive patients.
METHODS: Cardiac structure, systolic function, and hemodynamics were evaluated by two-dimensional M-mode echocardiography in diabetic and nondiabetic patients with essential hypertension.
RESULTS: Patients with hypertension with and without DM had the same end-systolic and end-diastolic dimensions, cardiac output, total peripheral resistance, and ejection fraction. Diabetic hypertensive patients had greater interventricular septum (1.32 +/- 0.20 vs 1.07 +/- 0.20 cm) and posterior wall (1.20 +/- 0.20 vs 1.00 +/- 0.10 cm) thickness than did nondiabetic hypertensive patients. Consequently, left ventricular mass index was greater in patients with hypertension and DM than in those without DM (158 +/- 45 vs 113 +/- 20 g/m2). With the use of Devereux criteria for recognition of LVH (left ventricular mass index above 134 g/m2 in men and above 110 g/m2 in women), 72% of the diabetic patients had LVH, whereas only 32% of the nondiabetic patients had LVH. Left ventricular contractility, as reflected by the ratio of end-systolic wall stress to end-systolic volume index, was decreased in diabetic compared with nondiabetic hypertensive patients.
CONCLUSIONS: The data suggest that DM accelerates the development of LVH in patients with essential hypertension independent of arterial pressure and, therefore, may contribute to the increased cardiovascular morbidity and mortality in patients with hypertension.

Entities:  

Mesh:

Year:  1992        PMID: 1533758

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  19 in total

1.  [Cardial target-organ damage in diabetes].

Authors:  W Motz; W Kerner
Journal:  Internist (Berl)       Date:  2011-05       Impact factor: 0.743

2.  Left ventricular mass in type 2 diabetes mellitus. A study employing a simple ECG index: the Cornell voltage.

Authors:  S V de Kreutzenberg; A Avogaro; A Tiengo; S Del Prato
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

Review 3.  Diabetes and the risk of heart failure.

Authors:  Ravi Dhingra; Ramachandran S Vasan
Journal:  Heart Fail Clin       Date:  2011-10-13       Impact factor: 3.179

Review 4.  Diabetes mellitus and cardiac function.

Authors:  M A Mahgoub; A S Abd-Elfattah
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

5.  Autonomic neuropathy tests correlate with left ventricular mass and cardiac diastolic function in normotensive patients with type 2 diabetes mellitus and without left ventricular hypertrophy.

Authors:  João S Felício; Flávia M Santos; Ana Carolina Cb de Souza; Karem M Felício; Arthur B Ribeiro; Maria T Zanella
Journal:  Exp Clin Cardiol       Date:  2010

Review 6.  Management of diabetic and hypertensive cardiovascular disease.

Authors:  Edward D Frohlich; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 7.  Should we treat prehypertension in diabetes? What are the cons?

Authors:  Ehud Grossman
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

8.  Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.

Authors:  Robert J Gropler
Journal:  Circulation       Date:  2009-04-21       Impact factor: 29.690

9.  Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats.

Authors:  Bhoomika R Goyal; Pravin Mesariya; Ramesh K Goyal; Anita A Mehta
Journal:  Mol Cell Biochem       Date:  2008-04-19       Impact factor: 3.396

10.  A comparison of left ventricular abnormalities associated with glucose intolerance in African Caribbeans and Europeans in the UK.

Authors:  N Chaturvedi; P M McKeigue; M G Marmot; P Nihoyannopoulos
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.